Skip to search formSkip to main contentSkip to account menu

Recombinant EphB4-HSA Fusion Protein

Known as: sEphB4-HSA 
A recombinant fusion protein composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC).
4640Background: EphB4, a receptor kinase expressed in most epithelial tumors, binds EphrinB2 to affect cancer cell growth… 
2020
2020
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).
TPS274Background: The EphB4/EphrinB2 pathway is a promising therapeutic target for patients with mCRPC. EphB4 expression is… 
2018
2018
A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).
285Background: EphrinB4, a receptor kinase, is associated with stage and survival in epithelial cancers. sEphB4 is a fusion… 
2016
2016
Circulating tumor cell analysis in a first-in-human phase I study of sEphB4-HSA, an inhibitor of EphrinB2-EphB4 signaling
2014
2014
Abstract 1758: Targeting EphB4 with a novel antibody in acute leukemia
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: EphB4, a receptor tyrosine kinase, binds to… 
2014
2014
In vivo efficacy of sEphB4-HSA combined with Bevacizumab.
2014
2014
Abstract 2601: EphB4/EphrinB2 targeting increases the efficacy of cisplatin in triple negative breast cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Triple negative breast cancer (TNBC) represents a… 
2013
2013
Abstract 4356: EphB4 as a novel therapeutic target for head-neck SCC.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Introduction: Receptor tyrosine kinase EphB4 and its… 
2012
2012
Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA.
The use of albumin fusion proteins as therapeutic drug candidates is an attractive approach to design novel biopharmaceuticals… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)